Roche employees raise funds for vulnerable children in over 90 communities around the world

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) employees in 70 countries and 141 sites come together to participate in the 2016 Roche Children's Walk, which takes place on the International Day of the African Child. All of the funds raised through the global event will be used to support children in need, either in local communities in which Roche operates or in Malawi, one of the world's poorest countries, ranking 173 out of 188 on the Human Development Index.

"The Roche Children’s Walk is our signature global annual event and we are proud to support children in need in over 90 communities around the world. We strongly believe that our support must be sustainable and this is why we partner with organisations that help local communities to learn and develop their own capabilities in time," says Severin Schwan, CEO of Roche. "Much of the funds raised around the world will go towards supporting schools and teachers in countries and areas where there is a dire need. In 2016, the company will again match the money raised by employees."

Roche employees have a long history of supporting education efforts in Malawi. Since 2003, the funds raised have helped over 17,000 pupils who were able to gain secondary education. Roche also supported young adults to learn a trade that allows them to find a job or create their own company. Over 100 students have graduated or will graduate from university with Roche's support, thus gaining tertiary education which is not easily accessible to students who come from an underprivileged background.

Over a period of five years, Roche partnered with UNICEF for the construction of a Teacher's Training Centre (TTC) in Malawi which will enable the training of 560 young teachers per year. Education coverage is particularly low, due to high primary school dropout and repetition rates, but also through the dramatic loss of life incurred in the 90s during the HIV/AIDS epidemic. The orphan centres as well as the TTC were handed back to their local communities and are now fully self-sustaining.

At the end of 2015, Roche embarked on a new collaboration with ActionAid Malawi, aiming to support the construction of four Model preschools (so called Community Based Childcare Centers) as well as improving another 20 further Satellite preschools. Construction on the four model preschools is almost completed, while the planning process in the satellite preschools is in its early phase. The purpose of this project is to improve the lives and well-being of approximately 4,300 children. In the Early Childhood Development (ECDs), the children will receive early childcare and education, as well as regular health monitoring and feeding. The ECDs will also enhance the capacity and motivation of 240 caregivers on site. The project will be completed by April 2019, at which time the centres should be self-sustaining.

About Roche Children's Walk
Since 2003, over 150,000 Roche employees have walked at 141 sites, raising over 12.5 million CHF to date. The Roche Children's Walk is the signature global event in the company. Roche employees have continuously raised money for children in need by joining the annual walk which takes place on 16th June - the International Day of the African Child. With the purpose of encouraging self-sustainable living through education and health programmes, money collected by Roche employees during the global event is matched by Roche. A portion of funds raised are used to support local children's initiatives, while the rest go toward children's initiatives in Malawi, one of the least developed countries in the world. With 62% of the population living below the international poverty line of USD 1.25 per day and 790.000 children orphaned due to HIV/AIDS, our goal is to foster long-term sustainable change by assisting with efforts such as providing food, education and health promotion for the children of Malawi.

About ActionAid Malawi
The Roger Federer Foundation has launched a ten year early childhood education initiative in Malawi with its partner ActionAid Malawi in 2011. ActionAid Malawi is a non-governmental national development organisation that was founded in Malawi in 1990. It is a member of the South Africa-based international federation of more than 40 national ActionAid organisations. However, ActionAid Malawi is an entirely local non-governmental organisation that operates and makes its decisions independently and is managed exclusively by local employees. It is focused on fighting poverty and is active in 14 of Malawi's districts. ActionAid Malawi specialises in helping rural and particularly isolated areas through long-term programmes. Involving local communities and fostering their sense of ownership are a particular focus of its work and part of its consistent approach. In its role as a consultant to the Malawian government, ActionAid Malawi gives this often marginalised segment of the population a voice in the capital city.

About United Nations International Children's Emergency Fund - UNICEF
Founded in 1946 and mandated by the United Nations General Assembly and guided by the Convention on the Rights of the Child, UNICEF advocates for the protection of children's rights, helps children across the world meet basic needs and expand their opportunities to reach their full potential. Working in 190 countries and territories to translate the commitment to the wellbeing of children into practical action, UNICEF focuses special efforts on reaching the most vulnerable and excluded children, to the benefit of all children, everywhere.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...